Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 5
1984 3
1985 4
1986 3
1987 9
1988 5
1989 6
1990 6
1991 6
1992 3
1993 4
1994 7
1995 8
1996 17
1997 33
1998 74
1999 109
2000 136
2001 162
2002 186
2003 168
2004 189
2005 174
2006 190
2007 169
2008 153
2009 132
2010 149
2011 124
2012 115
2013 103
2014 95
2015 83
2016 84
2017 63
2018 69
2019 58
2020 68
2021 72
2022 59
2023 46
2024 21

Text availability

Article attribute

Article type

Publication date

Search Results

2,883 results

Results by year

Filters applied: . Clear all
Page 1
Raloxifene hydrochloride.
Snyder KR, Sparano N, Malinowski JM. Snyder KR, et al. Am J Health Syst Pharm. 2000 Sep 15;57(18):1669-75; quiz 1676-8. Am J Health Syst Pharm. 2000. PMID: 11006795 Review.
The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and therapeutic role of raloxifene hydrochloride are reviewed. Raloxifene is a selective estrogen-receptor modulator (SERM) that has been approved for use in the prevention and treatment …
The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and therapeutic role of raloxifene hydrochloride are r …
Cardiovascular effects of raloxifene hydrochloride.
Saitta A, Morabito N, Frisina N, Cucinotte D, Corrado F, D'Anna R, Altavilla D, Squadrito G, Minutoli L, Arcoraci V, Cancellieri F, Squadrito F. Saitta A, et al. Cardiovasc Drug Rev. 2001 Spring;19(1):57-74. doi: 10.1111/j.1527-3466.2001.tb00183.x. Cardiovasc Drug Rev. 2001. PMID: 11314601 Review.
Raloxifene hydrochloride binds to the estrogen receptor and shows tissue-selective effects; thus, it belongs to a class of drugs recently described as selective estrogen receptor modulators (SERMs). ...Raloxifene has estrogen-agonist effects on bone and lipid …
Raloxifene hydrochloride binds to the estrogen receptor and shows tissue-selective effects; thus, it belongs to a class of dru …
Raloxifene.
Kellen JA. Kellen JA. Curr Drug Targets. 2001 Dec;2(4):423-5. doi: 10.2174/1389450013348263. Curr Drug Targets. 2001. PMID: 11732640 Review.
It is of obvious benefit to cancer patients to administer substances that combine minimal general toxicity with maximal oestrogen inhibition. Raloxifene is a relatively recent addition to a group of compounds loosely designated as antioestrogens, which implies their abilit …
It is of obvious benefit to cancer patients to administer substances that combine minimal general toxicity with maximal oestrogen inhibition …
Folic acid-conjugated raloxifene hydrochloride carbon nanotube for targeting breast cancer cells.
Jawahar N, De A, Jubee S, Reddy ES. Jawahar N, et al. Drug Dev Res. 2020 May;81(3):305-314. doi: 10.1002/ddr.21620. Epub 2019 Nov 29. Drug Dev Res. 2020. PMID: 31782825
CNTs were prepared based on the modified Staudenmaier process, where temperature and stirring speed were found to be the most influencing factor for particle size and entrapment of the drug raloxifene hydrochloride (RLX). The optimized formulation was produced with …
CNTs were prepared based on the modified Staudenmaier process, where temperature and stirring speed were found to be the most influencing fa …
Formulation and evaluation of raloxifene hydrochloride dry emulsion tablet using solid carrier adsorption technique.
Patel V, Patel C, Patel B, Thakkar H. Patel V, et al. Ther Deliv. 2021 Jul;12(7):539-552. doi: 10.4155/tde-2021-0025. Epub 2021 Jun 24. Ther Deliv. 2021. PMID: 34165001
Aim: The present study focused on the development of a dry emulsion tablet of raloxifene hydrochloride (RXF) using a solid carrier adsorption technique to enhance oral bioavailability. ...
Aim: The present study focused on the development of a dry emulsion tablet of raloxifene hydrochloride (RXF) using a solid car …
Raloxifene.
Seeman E. Seeman E. J Bone Miner Metab. 2001;19(2):65-75. doi: 10.1007/s007740170043. J Bone Miner Metab. 2001. PMID: 11281162 Review.
Raloxifene is a selective estrogen receptor modulator, a compound that has estrogen agonist activity at some sites and antagonist activity at others. ...These are surrogate endpoints of cardioprotection. There is no evidence that raloxifene reduces the incidence of …
Raloxifene is a selective estrogen receptor modulator, a compound that has estrogen agonist activity at some sites and antagonist act …
Long-term raloxifene for postmenopausal osteoporosis.
Recker RR, Mitlak BH, Ni X, Krege JH. Recker RR, et al. Curr Med Res Opin. 2011 Sep;27(9):1755-61. doi: 10.1185/03007995.2011.606312. Epub 2011 Jul 25. Curr Med Res Opin. 2011. PMID: 21787127 Review.
BACKGROUND: Due to the chronic nature of osteoporosis and the risk of invasive breast cancer, raloxifene 60 mg/day (raloxifene) is intended to be used for long-term treatment (treatment >3 years). ...The most important studies were the Multiple Outcomes of Ral …
BACKGROUND: Due to the chronic nature of osteoporosis and the risk of invasive breast cancer, raloxifene 60 mg/day (raloxifene …
Raloxifene: cardiovascular considerations.
Abu Fanne R, Brzezinski A, Danenberg HD. Abu Fanne R, et al. Mini Rev Med Chem. 2007 Aug;7(8):871-6. doi: 10.2174/138955707781387911. Mini Rev Med Chem. 2007. PMID: 17692049 Review.
These unique properties offer the possibility to attain the beneficial effects of estrogen while avoiding its carcinogenic effect and the accompanying adverse reactions. Here we review the different effects of raloxifene- a protype second generation SERM on the cardiovascu …
These unique properties offer the possibility to attain the beneficial effects of estrogen while avoiding its carcinogenic effect and the ac …
In reply.
Urushihara H. Urushihara H. Menopause. 2014 Jan;21(1):110. doi: 10.1097/GME.0000000000000158. Menopause. 2014. PMID: 24326283 No abstract available.
2,883 results